Two prostate-specific antigens, gamma-seminoprotein and beta-microseminoprotein

Area of Science:

• Urology
• Biochemistry
• Oncology

Background:

• Prostate-specific antigen (PSA), also known as gamma-seminoprotein (gamma-Sm), is a key biomarker in prostate cancer diagnostics.
• The prostatic acid phosphatase (PAP) test is a less sensitive and specific method for prostate cancer detection compared to PSA.
• Research into prostate-specific antigens is expanding due to their diagnostic potential.

Purpose of the Study:

• To review the physicochemical properties and clinical significance of gamma-seminoprotein (PSA) and beta-microseminoprotein (beta-MSP).
• To highlight the advantages of PSA over the PAP test in urology.
• To discuss the utility of these prostate-specific antigens in identifying the origin of metastatic tumors.

Main Methods:

• Literature review of physicochemical properties and clinical significance of gamma-Sm (PSA) and beta-MSP.
• Immunohistologic studies to determine tissue origin of these proteins.
• Analysis of amino acid sequences and molecular weights.
• Assessment of enzymatic activity (chymotrypsin-like) of gamma-Sm (PSA).

Main Results:

• Gamma-Sm (PSA) and beta-MSP are exclusively found in the prostate gland.
• Gamma-Sm (PSA) is a glycoprotein with a molecular weight of 26,079 (peptide portion) and exhibits chymotrypsin-like activity.
• Beta-MSP has a molecular weight of 10,652 and lacks alanine residues in its amino acid sequence.
• Both proteins are useful in determining the origin of metastatic tumors.

Conclusions:

• Gamma-Sm (PSA) is a more sensitive and specific marker for prostate cancer diagnosis and monitoring than PAP.
• The study of prostate-specific antigens like PSA and beta-MSP is crucial for advancing urological diagnostics and cancer research.
• These prostate-specific proteins offer valuable insights into prostate cancer and metastasis.